Results 211 to 220 of about 126,758 (293)

Blinatumomab for treatment of children with acute lymphoblastic leukaemia in Hong Kong: A cost‐effectiveness analysis

British Journal of Haematology, EarlyView.
Summary To assess the cost‐effectiveness of blinatumomab plus chemotherapy for paediatric patients from Hong Kong public healthcare provider's perspective, a 10‐year Markov model was designed to simulate outcomes in paediatric patients with newly diagnosed standard‐risk B‐cell ALL at: (1) average risk and (2) high risk of relapse.
Mingjun Rui, Yin Ting Cheung, Hui Zhang, Qiran Wei, Yingcheng Wang, Jiaqi Shi, Chi Kong Li, Joyce H. S. You   +7 more
wiley   +1 more source

PD-L1-armored CD19/CD22 dual-targeted CAR-T cell co-infusion bridging to allogeneic hematopoietic stem cell transplantation achieves 7-year sustained remission in an adult patient with early relapsed, chemorefractory B-cell acute lymphoblastic leukemia: a case report. [PDF]

Front Immunol
Hua H, Wen S, Han X, Liu X, Zhou Z, Song Z, Zhang X, Wang F.   +7 more
europepmc   +1 more source

Phenotype‐specific immune profiles and outcomes in childhood autoimmune neutropenia: A 20‐year cohort study

British Journal of Haematology, EarlyView.
Summary Childhood autoimmune neutropenia (AIN) encompasses heterogeneous entities; phenotype‐specific immunological profiles and their relationship to infection outcomes remain incompletely defined. To characterise clinical, immunological and long‐term outcomes across distinct phenotypes of childhood AIN.
Ioanna Saougou, Chrysoula Kosmeri, Nikolaos Chaliasos, Irene Mavroudi, Charalampos Pontikoglou, Alexandros Makis   +5 more
wiley   +1 more source

CAR-T cell therapy for autoimmune diseases: current clinical trial landscape and the next wave of development. [PDF]

Front Immunol
Chen Q, Zhu Y, Xu Q, He Y, Wang Y, Wang Z, Dong W.   +6 more
europepmc   +1 more source

CD21⁺CD11c⁺ B cells predicting handgrip strength decline in older adults. [PDF]

Front Aging
Mabe-Castro D, Mabe-Castro M, Varón LS, Navarrete MA, Castillo-Aguilar M, Núñez-Espinosa C.   +5 more
europepmc   +1 more source

Schnitzler Syndrome as an Autoinflammatory Disease Driven by B‐Cell‐Specific Somatic MYD88 Mutation

Allergy, EarlyView.
Yuyi Zhou, Yoko Ueki, Naoya Iwata, Hiroshi Oue, Kentaro Kato, Mengyan Li, Kazushi Izawa, Tomoyasu Jo, Seishi Ogawa, Kenji Kabashima, Naotomo Kambe   +10 more
wiley   +1 more source

Comparative effectiveness of chimeric antigen receptor (CAR) T‐cell therapy versus historical controls in patients with relapse/refractory aggressive B‐cell lymphoma: An indirect treatment comparison in the real‐world setting

British Journal of Haematology, EarlyView.
Summary Single‐arm studies demonstrate dramatic improvements in survival in patients with relapsed/refractory (R/R) aggressive B‐cell lymphomas but with significant toxicities and at exceptionally high costs. The objective of this study was to evaluate the real‐world health outcomes of aggressive B‐cell lymphoma patients treated with publicly funded ...
Pierre J. A. Villeneuve, Lee Mozessohn, Nibene H. Somé, Rebecca E. Mercer, Lisa Masucci, Tom Kouroukis, Chris Bredeson, Suriya Aktar, Qi Guan, Anca Prica, Christine I. Chen, Danielle Rodin, Matthew Cheung, Munaza Chaudhry, Scott Gavura, Cassandra McKay, William W. L. Wong, Kelvin K. W. Chan   +17 more
wiley   +1 more source

Fit cells, fertile ground: Immunometabolic programming and bone marrow niche support in durable CAR T cell response in leukemia. [PDF]

Mol Ther Oncol
Wang X, Goldberg L.
europepmc   +1 more source

Response‐adapted consolidation and salvage strategies in secondary central nervous system lymphoma: Insights from a multicentre cohort

British Journal of Haematology, EarlyView.
Summary Secondary central nervous system lymphoma (SCNSL) remains a rare but challenging manifestation of aggressive lymphomas, with limited prospective data to guide treatment decisions in the modern therapeutic era. We conducted a multicentre retrospective cohort study of 105 consecutively treated adult patients diagnosed with SCNSL between 2016 and ...
Farina Eigendorff, Fabian Görke, Vanja Zeremski, Sophia Wollnitza, Evgenii Shumilov, Georg Lenz, Ellen Obstfelder, Inken Hilgendorf, Vladan Vučinić, Andreas Hochhaus, Ulf Schnetzke   +10 more
wiley   +1 more source

Comparative efficacy and long-term survival of CD19/22 versus CD19 CAR-T immunotherapy in Relapsed/Refractory B-ALL with TP53 alterations. [PDF]

J Transl Med
Tang Y, Li M, Cui Q, Liu S, Li T, Qiu H, Kang L, Yu L, Wu D, Tang X.   +9 more
europepmc   +1 more source